Current guidelines for genetic testing include screening for the presence of activating alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), or v-Raf murine sarcoma viral oncogene homolog B (BRAF) prior to the initiation of first-line treatment in NSCLC [2]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.